Log in to save to my catalogue

High levels of AXL expression in untreated EGFR‐mutated non‐small cell lung cancer negatively impact...

High levels of AXL expression in untreated EGFR‐mutated non‐small cell lung cancer negatively impact...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9899603

High levels of AXL expression in untreated EGFR‐mutated non‐small cell lung cancer negatively impacts the use of osimertinib

About this item

Full title

High levels of AXL expression in untreated EGFR‐mutated non‐small cell lung cancer negatively impacts the use of osimertinib

Publisher

England: John Wiley & Sons, Inc

Journal title

Cancer science, 2023-02, Vol.114 (2), p.606-618

Language

English

Formats

Publication information

Publisher

England: John Wiley & Sons, Inc

More information

Scope and Contents

Contents

For non‐small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations, the initial therapeutic interventions will have crucial impacts on their clinical outcomes. Drug tolerant factors reportedly have an impact on EGFR‐tyrosine kinase inhibitor sensitivity. This prospective study investigated the impacts of drug tol...

Alternative Titles

Full title

High levels of AXL expression in untreated EGFR‐mutated non‐small cell lung cancer negatively impacts the use of osimertinib

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9899603

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9899603

Other Identifiers

ISSN

1347-9032

E-ISSN

1349-7006

DOI

10.1111/cas.15608

How to access this item